Oncurious is an oncology company focused on the development of TB-403 for the treatment of pediatric brain tumors. TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma, a rare, life-threatening brain tumor that mainly affects children. Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. Peter Carmeliet (VIB/KU Leuven) and Rakesh Jain (Massachusetts General Hospital at Harvard -Boston) were the first to highlight the role of PlGF in medulloblastoma. (Cell, 152, 1065-76, 2013).

Oncurious was incorporated in 2015. It is a ThromboGenics–VIB joint venture with ThromboGenics being the majority shareholder.